Effect of adenosine and histamine receptor stimulation on canine histamine release to pentagastrin.
The effects of adenosine and histamine 2 and histamine 3 receptor agonists on the regulation of gastric histamine release were examined in anesthetized mixed-breed dogs. All compounds were infused directly into the gastrosplenic artery to avoid perturbations in systemic hemodynamics, and the gastric histamine release was stimulated with pentagastrin. The histamine concentration in plasma samples was measured utilizing gas chromatography-negative-ion chemical ionization mass spectroscopy. Pentagastrin consistently stimulated gastric histamine release with the peak stimulation occurring at 5 min, while neither 30 nor 100 microM of adenosine altered the effect of pentagastrin on histamine release. In addition, theophylline at 20 microg/ml exhibited no effect on stimulated histamine release. The histamine 2 receptor agonist dimaprit, at 1 and 3 microM, attenuated pentagastrin-stimulated histamine release at the 5-min time period, but the difference was not sustained at later time points (histamine release from 1.4 +/- 0.6 to 92 +/- 18 ng/min at 5 min with pentagastrin alone; from 1.2 +/- 0.5 to 32 +/- 11 ng/min with pentagastrin plus 1 microM dimaprit, and from 2.0 +/- 1.1 to 32 +/- 9 ng/min with pentagastrin plus 3 microM dimaprit), while the H2 receptor antagonist cimetidine exhibited no effect on pentagastrin-stimulated histamine release. The histamine 3 receptor agonist (R)-alpha-methylhistamine attenuated the pentagastrin-stimulated histamine release at the 5- and 10-min time periods only at 1 microM without showing any effect at the higher (3 microM) concentration. Thioperamide, a H3 receptor antagonist, did not modify pentagastrin-stimulated histamine release. These data demonstrate that adenosine has no modulatory role on gastric histamine release, but histamine via H2 and H3 histamine receptors could modulate its own release but only to a modest degree as compared with the potent effect of the paracrine hormone somatostatin.
Payne
N A
NA
Division of Clinical Pharmacology and Toxicology, University of Colorado Health Sciences Center, Denver 80262, USA.
Gerber
J G
JG
D000241:Adenosine / Q000494:pharmacology*; D000818:Animals; D017259:Dimaprit / Q000494:pharmacology; D004195:Disease Models, Animal; D004285:Dogs; D005260:Female; D008401:Gas Chromatography-Mass Spectrometry; D005753:Gastric Mucosa / Q000187:drug effects* / Q000378:metabolism; D017442:Histamine Agonists / Q000494:pharmacology*; D006633:Histamine Antagonists / Q000494:pharmacology*; D006636:Histamine Release / Q000187:drug effects*; D008297:Male; D008761:Methylhistamines / Q000494:pharmacology; D015999:Multivariate Analysis; D010418:Pentagastrin / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology; D011968:Receptors, Histamine / Q000097:blood / Q000187:drug effects*; D012016:Reference Values; D012039:Regional Blood Flow / Q000187:drug effects; D018709:Statistics, Nonparametric; D013806:Theophylline / Q000494:pharmacology
D017442:Histamine Agonists; D006633:Histamine Antagonists; D008761:Methylhistamines; D010880:Piperidines; D011968:Receptors, Histamine; D013806:Theophylline; D010418:Pentagastrin; C052075:thioperamide; D000241:Adenosine; D017259:Dimaprit